Publikationen - neuroendokrine pankreastumore

Direkt zum Seiteninhalt

Hauptmenü:

Publikationen


Bartsch DK, Albers MB.
Controversies in surgery for multiple endocrine neoplasia type 1-associated Zollinger- Ellison syndrome.
International Journal of Endocrine Oncology 4: 263-371 (2015)

Bartsch DK, Slater EP, Albers M, Knoop R, Chaloupka B, Lopez CL, Fendrich V, Kann PH, Waldmann J.
Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain.
J Clin Endocrinol Metab. 2014 Nov; 99(11):E2387-91.

Partelli S, Inama M, Rinke A, Begum N, Valente R, Fendrich V, Tamburrino D. Keck T, Caplin ME, Bartsch DK, Thirlwell C, Fusai G, Falconi M.
Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases.
Neuroendocrinology 102:68-76 (2015)

Münzberg C, Höhn K, Krndija D, Maaß U, Bartsch DK, Slater EP, Oswald F, Walther P, Seufferlein T, von Wichert G.
IGF-1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells.
J Cell Mol Med 19:948-959 (2015)

Lichtenauer UD, Di Dalmazi G, Slater EP, Wieland T, Kuebart A, Schmittfull A, Schwarzmayr T, Diener S, Wiese D, Thasler WE, Reincke M, Meitinger T, Schott M, Fassnacht M, Bartsch DK, Strom TM, Beuschlein F.
Frequency and clinical correlates of somatic Ying Yang 1 mutations in sporadic insulinomas.
J Clin Endocrinol Metab 100:E776-782. (2015)

Klieser E, Illig R, Státtner S, Primavesi F, Jáger T, Swierczynski S, Kiesslich T, Kemmerling R, Bollmann C, Di Fazio P, Neureiter D.
EndoplasmicReticulum Stress in Pancreatic Neuroendocrine Tumors is Linked to Clinicopathological Parameters and Possible Epigenetic Regulations.
Anticancer Res 35:6127-6136 (2015)

Geis C, Fendrich V, Rexin P, Di Fazio P, Bartsch DK, Ocker M, Quint K,Heverhagen AE.
Ileal neuroendocrine tumors show elevated activation of mammalian target of rapamycin complex.
J Surg Res 194:388-393 (2015)

Krug S, Kühnemuth B, Griesmann H, Neesse A, Mühlberg L, Boch M, Kortenhaus J, Fendrich V, Wiese D, Sipos B, Friemel J, Gress TM, Michl P.
CUX1: a modulator of tumour aggressiveness in pancreatic neuroendocrine neoplasms
Endocr Relat Cancer. 2014 Dec; 21(6): 879-90.

Geis C, Fendrich V, Rexin P, Di Fazio P, Bartsch DK, Ocker M, Quint K, Heverhagen AE.
Ileal neuroendocrine tumors show elevated activation of mammalian target of rapamycin complex.
J Surg Res. 2014 Nov 5. pii: S0022-4804(14)00982-2

Dieckhoff P, Runkel H, Daniel H, Wiese D, Koenig A, Fendrich V, Bartsch DK, Moll R, Müller D, Arnold R, Gress T, Rinke A.
Well-differentiated neuroendocrine neoplasia: relapse-free survival and predictors of recurrence after curative intended resections.
Digestion. 2014; 90(2):89-97

Bartsch DK, Dietzel K, Bargello M, Matthaei E, Kloeppel G, Esposito I, Heverhagen JT, Gress TM, Slater EP, Langer P.
Multiple small "imaging" branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade pancreatic intraepithelial neoplasia?
Fam Cancer. 2013 Mar;12(1):89-96.

Fendrich V, Sparn M, Lauth M, Knoop R, Plassmeier L, Bartsch DK, Waldmann J.
Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.
Pancreatology. 2013 Sep-Oct;13(5):502-7. Epub 2013 Aug 20.

Plassmeier L, Knoop R, Waldmann J, Kesselring R, Buchholz M, Fichtner-Feigl S, Bartsch DK, Fendrich V.
Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer.
Langenbecks Arch Surg. 2013 Oct;398(7):989-96. Epub 2013 Aug 30.

Fensterer H, Schade-Brittinger C, Müller HH, Tebbe S, Fass J, Lindig U, Settmacher U, Schmidt WE, Märten A, Ebert MP, Kornmann M, Hofheinz R, Endlicher E, Brendel C, Barth PJ, Bartsch DK, Michl P, Gress TM; Arbeitsgemeinschaft Internistische Onkologie.
Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).
Ann Oncol. 2013 Oct;24(10):2576-81. Epub 2013 Jul 29.

Heverhagen AE, Geis C, Fendrich V, Ramaswamy A, Montalbano R, Di Fazio P, Bartsch DK, Ocker M, Quint K.
Embryonic Transcription Factors CDX2 and Oct4 Are Overexpressed in Neuroendocrine Tumors of the Ileum: A Pilot Study.
Eur Surg Res. 2013 Jul 23;51(1-2):14-20. [Epub ahead of print]

López CL, Langer P, Waldmann J, Fendrich V, Sitter H, Nies C, Bartsch DK.
Shortness: an unknown phenotype of multiple endocrine neoplasia type 1.
Eur J Endocrinol. 2013 Jul;169(1):133-7.

Fendrich V, Maschuw K, Rehm J, Buchholz M, Holler JP, Slater EP, Bartsch DK, Waldmann J.
Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors.
ScientificWorldJournal. 2012;2012:529151. Epub 2012 Dec 27.

Capurso G, Fendrich V, Rinzivillo M, Panzuto F, Bartsch DK, Delle Fave G.
Novel molecular targets for the treatment of gastroenteropancreatic endocrine tumors: answers and unsolved problems.
Int J Mol Sci. 2012 Dec 20;14(1):30-45.

Habbe N, Fendrich V, Heverhagen A, Ramaswamy A, Bartsch DK.
Outcome of surgery for ileojejunal neuroendocrine tumors.
Surg Today. 2013 Oct;43(10):1168-74.Epub 2012 Nov 11.

Bartsch DK, Waldmann J*, Fendrich V, Boninsegna L, Lopez CL, Partelli S, Falconi M.
Impact of lymphadenectomy on survival in patients with sporadic gastrinoma.
Br J Surg. 2012 Sep; 99(9):1234-40

Falconi M, Bartsch DK, Eriksson b, Klöppel G, Lopes JM, O’Connor JM, Salazar R, Taal BG, Vullierme MP, O’Toole D;
Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive System: well-differentiated pancreatic non-functioning tumors.
Neuroendocrinology, 2012, 95(2):120-34

Krug S, Bartsch DK, Schober M, Librizzi D, Pfestroff A, Burbelko M, Moll R, Michl P, Gress TM.
Successful selective internal radiotherapy SIRT) in a patient with a malignant solid pseudopapillary pancreatic neoplasm (SPN).
Pancreatology. 2012, 12(5):423-7

Kann PH, Bartsch DK, Langer P, Waldmann J, Hadji P, Pfützner A, Klüsener J.
Peripheral bone mineral density in correlation to disease-related predisposing conditions in patients with multiple endocrine neoplasia type 1.
J Endocrinol Invest. 2012, 35:573-9

Fendrich V, Maschuw K, Waldmann J, Buchholz M, Rehm J, Gress T.M, Bartsch D.K, König A.
Epithelial-Mesenchymal Transition is a critical step in tumorgenesis of pancreatic neuroendocrine tumors.
Cancers 2012, 4, 281-294

Fendrich V, Maschuw K, Rehm J, Buchholz M, Holler JP, Slater EP, Bartsch DK, Waldmann J.
Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors.
The Scientific World Journal 2012, 2012:529151

Lopez CL, Falconi M, Waldmann J, Boninsegna L, Fendrich V, Goretzki PK, Langer P, Kann PH, Partelli S, Bartsch DK.
Partial pancreaticoduodenetomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1.
Ann Surg, 2012, 257(2):308-14

Fendrich V, Merz MK, Waldmann J, Langer P, Heverhagen AE, Dietzel K, Bartsch DK
Neuroendocrine Pancreatic TumorsAre Risk Factors for Pancreatic Fistula after Pancreatic Surgery
Dig Surg, 2011, 28:263-9

Lopez CL, Waldmann J, Fendrich V, Langer P, Kann PH, Bartsch DK
Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1
Langenbecks Arch Surg, 2011, 396(8):1187-96

Fendrich V, Michl P, Habbe N, Bartsch DK
Liver-specific therapies for metastases of neuroendocrine pancreatic tumors
World J Hepatol, 2010, 27(10):367-73

Fendrich V, Bartsch DK
Diagnostik und operative Therapie des Gastrinoms, Vipoms, Glukagonoms, Somatostatinoms und nichtfunktioneller Pankreastumoren
Zentralbl Chir, 2010, 135(3):210-7

Fendrich V, Chen NM, Neef M, Waldmann J, Buchholz M, Feldmann G, Slater EP, Maitra A, Bartsch DK
The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer
Gut, 2010, 59(5):630-7

Fendrich V, Waldmann J, Bartsch DK, Langer P.
Surgical management of pancreatic endocrine tumors.
Nat Rev Clin Oncol 2009 ;6:419-28.

Langer P, Fendrich V, Bartsch DK.
Minimally invasive resection of neuroendocrine pancreatic tumors.
Chirurg 2009; 80:105-12.

Fendrich V, Ramerth R, Waldmann J, Maschuw K, Langer P, Bartsch DK, Slater EP, Ramaswamy A, Rothmund M.
Sonic hedgehog and Pancreatic-duodenal homeobox 1 (Pdx1) expression distinguish between duodenal and pancreatic gastrinomas.
Endocr Relat Cancer 2009; 16:613-22.

Fendrich V, Waldmann J, Schlosser K, Bartsch DK, Rothmund M, Gerdes B.
Multiple primary malignancies in patients with sporadic pancreatic endocrine tumors.
J Surg Oncol 2008; 97:592-5.

Fendrich V, Langer P, Waldmann J, Bartsch DK, Rothmund M.
The management of sporadic and MEN-1-gastrinomas.
Br J Surg. 2007; 94:1331-1341

Fendrich V, Langer P.
Minimally invasive surgery for pancreatic endocrine tumours.
Br J Surg 2007; 94:1187-1188

Fendrich V, Habbe N, Celik I, Langer P, Zielke A, Bartsch DK, Rothmund M.
Operative Therapie und Langzeitüberleben bei neuroendokrinen Pankreastumoren - Erfahrungen bei 144 Patienten.
Dtsch Med Wochenschr. 2007; 2:195-200

Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy A, Rothmund M.
An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors.
Ann Surg 2006; 244:845-853

Bartsch DK, Fendrich V, Langer P, Celik I, Kann PH, Rothmund M.
Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1.
Ann Surg 2005 Dec; 242:757-764

Langer P, Rothmund M, Bartsch DK.
Prophylactic pancreas surgery.
Chirurg 2006; 77:25-32

Kann PH, Rothmund M, Zielke A.
Endoscopic ultrasound imaging of insulinomas: limitations and clinical relevance.
Exp Clin Endocrinol Diabetes 2005; 113:471-4

Langer P, Bartsch DK, Fendrich V, Kann PH, Rothmund M, Zielke A.
Minimal-invasive operative treatment of organic hyperinsulinism.
Dtsch Med Wochenschr 2005; 130:508-13

Fendrich V, Bartsch DK, Langer P, Zielke A, Rothmund M.
Zollinger-Ellison-Syndrom - Das gewandelte Verständnis der Chirurgie.
Chirurg 2005; 76:217-226

Langer P, Kann PH, Fendrich V, Richter G, Diehl S, Rothmund M, Bartsch DK.
Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1.
World J Surg 2004; 28:1317-1322

Fendrich V, Bartsch DK, Langer P, Zielke A, Rothmund M.
Diagnosis and therapy in 40 patients with insulinoma.
Dtsch Med Wochenschr 2004; 129:941-946

Wild A, Ramaswamy A, Langer P, Celik I, Fendrich V, Chaloupka B, Simon B, Bartsch DK.
Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors.
J Clin Endocrinol Metab 2003; 88:1367-1373.

Bartsch DK, Langer P, Wild A, Schilling T, Celik I, Rothmund M, Nies C.
Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance?
Surgery 2000; 128:958-66

Bartsch DK, Schilling T, Ramaswamy A, Gerdes B, Celik I, Wagner HJ, Simon B, Rothmund M.
Management of nonfunctioning islet cell carcinomas.
World J Surg 2000; 24:1418-24


 

   Prof. Dr. med. D.K. Bartsch


 
 
 
 
Zurück zum Seiteninhalt | Zurück zum Hauptmenü